Effect of sildenafil on reperfusion function, infarct size, and cyclic nucleotide levels in the isolated rat heart model - PubMed (original) (raw)
Effect of sildenafil on reperfusion function, infarct size, and cyclic nucleotide levels in the isolated rat heart model
Eugene Francois du Toit et al. Cardiovasc Drugs Ther. 2005 Jan.
Abstract
We have previously shown that NO-donor induced elevation in myocardial cGMP levels is associated with improved reperfusion function of the isolated rat heart. The phosphodiesterase 5 (PDE 5) inhibitor, sildenafil could potentially increase myocardial cGMP levels and thus protect the heart against ischaemic/reperfusion injury.
Methods: To test our hypothesis we treated the isolated working rat heart with vehicle, OR sildenafil (10, 20, 50, 100, 200 nM), OR sildenafil (50 nM) plus a sarcolemmal (HMR 1098) or a mitochondrial (5-Hydroxydecanoate (5-HD)) K(ATP) channel blocker. Hearts were then subjected to 20 min global, or 35 min regional ischaemia at 37( composite function)C before reperfusion function (aortic output, coronary flow and aortic pressure) and infarct size were documented. Pre-ischaemic, ischaemic and reperfusion myocardial cAMP and cGMP concentrations were determined.
Results: Low concentrations of sildenafil (10, 20 and 50 nM) improved reperfusion aortic output (AO) recovery (61.4+/- 4.5%, 64.8 +/- 5.2% and 62.3 +/- 5.0% vs. 45.4 +/- 3.8% for controls (p < 0.05)) and infarct size, while high concentrations (200 nM) worsened AO recovery (24.9 +/- 4.9.0%, p < 0.05). Myocardial cGMP levels of ischaemic tissue were elevated (34.7 +/- 2.4 vs. 27.3 +/- 2.2 pmol/g ww) and cAMP levels were suppressed (0.59 +/- 0.03 vs. 0.87 +/- 0.06 nmol/g ww) in the sildenafil (50 nM) treated hearts. Co-perfusion with sildenafil plus HMR 1098 decreased AO recovery (21.7 +/- 7.6% vs. 62.3 +/- 5.0% for sildenafil alone, p < 0.05) and increased infarct size (29.7 +/- 2.04% vs. 8.6 +/- 2.39% for sildenafil alone, p < 0.05).Similarly, sildenafil plus 5-HD decreased reperfusion AO recovery (44.4 +/- 6.0% vs. 62.3 +/- 5.0% for sildenafil alone, p < 0.05) and increased infarct size (33.8 +/- 1.62% vs. 8.6 +/- 2.39% for sildenafil alone, p < 0.05).
Conclusions: (1) Pretreatment with low concentrations of sildenafil (20-50 nM) improves, while higher concentrations (200 nM) worsen reperfusion function in this model. (2) Low concentrations of sildenafil (20-50 nM) decrease infarct size while the higher concentrations had no effect. (3) These protective properties of low concentrations of sildenafil may be related to its cGMP elevating and cAMP suppressing effects in the ischaemic heart. (4) Possible end-effectors for sildenafil in the ischaemic heart include the mitochondrial and sarcolemmal K(ATP) channel.
Similar articles
- Cardioprotection with sildenafil, a selective inhibitor of cyclic 3',5'-monophosphate-specific phosphodiesterase 5.
Das S, Maulik N, Das DK, Kadowitz PJ, Bivalacqua TJ. Das S, et al. Drugs Exp Clin Res. 2002;28(6):213-9. Drugs Exp Clin Res. 2002. PMID: 12776574 - Sildenafil citrate (viagra) induces cardioprotective effects after ischemia/reperfusion injury in infant rabbits.
Bremer YA, Salloum F, Ockaili R, Chou E, Moskowitz WB, Kukreja RC. Bremer YA, et al. Pediatr Res. 2005 Jan;57(1):22-7. doi: 10.1203/01.PDR.0000147736.27672.15. Epub 2004 Nov 5. Pediatr Res. 2005. PMID: 15531735 - Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits.
Salloum FN, Takenoshita Y, Ockaili RA, Daoud VP, Chou E, Yoshida K, Kukreja RC. Salloum FN, et al. J Mol Cell Cardiol. 2007 Feb;42(2):453-8. doi: 10.1016/j.yjmcc.2006.10.015. Epub 2006 Dec 8. J Mol Cell Cardiol. 2007. PMID: 17157308 Free PMC article. - Cardioprotection with sildenafil: implications for clinical practice.
Raja SG. Raja SG. Curr Med Chem. 2006;13(26):3155-64. doi: 10.2174/092986706778742927. Curr Med Chem. 2006. PMID: 17168704 Review. - Sildenafil in ophthalmology: An update.
Arora S, Surakiatchanukul T, Arora T, Cagini C, Lupidi M, Chhablani J. Arora S, et al. Surv Ophthalmol. 2022 Mar-Apr;67(2):463-487. doi: 10.1016/j.survophthal.2021.06.004. Epub 2021 Jun 25. Surv Ophthalmol. 2022. PMID: 34175342 Review.
Cited by
- Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis.
Soulaidopoulos S, Terentes-Printzios D, Ioakeimidis N, Tsioufis KP, Vlachopoulos C. Soulaidopoulos S, et al. Eur Heart J Cardiovasc Pharmacother. 2024 Aug 14;10(5):403-412. doi: 10.1093/ehjcvp/pvae029. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38777751 Free PMC article. - Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives.
ElHady AK, El-Gamil DS, Abdel-Halim M, Abadi AH. ElHady AK, et al. Pharmaceuticals (Basel). 2023 Sep 6;16(9):1266. doi: 10.3390/ph16091266. Pharmaceuticals (Basel). 2023. PMID: 37765073 Free PMC article. Review. - Pretreatment with tadalafil attenuates cardiotoxicity induced by combretastatin A4 disodium phosphate in rats.
Nagashima Y, Tochinai R, Sekizawa SI, Kato D, Nakagawa T, Tsuru Y, Tatewaki Y, Mutoh T, Taki Y, Kuwahara M. Nagashima Y, et al. J Toxicol Pathol. 2023 Jul;36(3):151-158. doi: 10.1293/tox.2022-0143. Epub 2023 Feb 15. J Toxicol Pathol. 2023. PMID: 37577366 Free PMC article. - Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review.
Corbic M, Sretenovic J, Zivkovic V, Jakovljevic V, Nikolic Turnic T. Corbic M, et al. Iran J Public Health. 2023 May;52(5):870-879. doi: 10.18502/ijph.v52i5.12704. Iran J Public Health. 2023. PMID: 37484720 Free PMC article. Review. - Changes in Left Ventricular Ejection Fraction and Oxidative Stress after Phosphodiesterase Type-5 Inhibitor Treatment in an Experimental Model of Retrograde Rat Perfusion.
Krivokapic M, Alisultanovich Omarov I, Zivkovic V, Nikolic Turnic T, Jakovljevic V. Krivokapic M, et al. Medicina (Kaunas). 2023 Feb 24;59(3):458. doi: 10.3390/medicina59030458. Medicina (Kaunas). 2023. PMID: 36984459 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical